Matthias Kretzler
Professor of Medicine University of Michigan
Seminars
Tuesday 17th March 2026
Panel Discussion: What Does Cardiorenal Mean to You? Defining Cardiorenal in a Rapidly Evolving Therapeutic Landscape
8:00 am
- Exploring different definitions of cardiorenal across clinical practice, research, and industry
- Identifying patient populations at highest risk and challenges in consistent diagnosis
- Examining whether cardiorenal primarily reflects CKD-driven CV risk, heart failure overlap, or a broader spectrum
- Considering how pharma, academia, and clinicians can align on trial design and endpoints for cardiorenal therapies
Wednesday 18th March 2026
Panel Discussion: Data Sources in Nephrology Drug Development: Choosing Wisely, Mitigating Bias, and Maximizing Impact
3:00 pm
- Sharing experience using different data sources (clinical trials, registries, EHRs, biobanks, biopsies) for drug development – from discovery through regulatory approval and post-market
- Comparative strengths and limitations of each data source: e.g. trial data offers control and randomization; registry/EHR data offers large-scale, real-world generalizability but more noise; biopsy samples offer deep mechanistic insight but are invasive and limited in availability
- Strategies to handle missing, incomplete, or biased data: statistical techniques, data linkage, standard operating procedures for sample collection, dealing with confounders, ensuring representative sampling
- How to align data sourcing strategy with regulatory and payer requirements: the evidentiary standards, reporting, validation, transparency, reproducibility
Wednesday 18th March 2026
Closing the Innovation Loop: Mechanistic Trials as a Tool for Precision Medicine in 2026
3:30 pm
- Integrating deep multiscalar data sets from biopsy cohort studies (NEPTUNE, KPMP, BEAT-DKD) has allowed to build a molecular map of the kidney in health and disease
- Mechanistic trials with entry and exit biomarkers and biopsies now allow to define treatment responses to experimental therapies
- First success in rare and common diseases will be presented
